Atox Bio
As of the edition of 20 October 2026, Atox Bio runs 1 drug; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| CD28 T-cell-specific surface glycoprotein CD28 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Atox Bio needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 3 trials led
- Urinary and reproductive: 2 trials led
- Bones, joints and muscles: 1 trials led